NZ628491A - Substituted prolines / piperidines as orexin receptor antagonists - Google Patents

Substituted prolines / piperidines as orexin receptor antagonists

Info

Publication number
NZ628491A
NZ628491A NZ628491A NZ62849113A NZ628491A NZ 628491 A NZ628491 A NZ 628491A NZ 628491 A NZ628491 A NZ 628491A NZ 62849113 A NZ62849113 A NZ 62849113A NZ 628491 A NZ628491 A NZ 628491A
Authority
NZ
New Zealand
Prior art keywords
orexin receptor
piperidines
receptor antagonists
substituted prolines
compounds
Prior art date
Application number
NZ628491A
Other languages
English (en)
Inventor
Theodore Kamenecka
Rong Jiang
Xinyi Song
Original Assignee
Eolas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eolas Therapeutics Inc filed Critical Eolas Therapeutics Inc
Publication of NZ628491A publication Critical patent/NZ628491A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NZ628491A 2012-02-07 2013-02-06 Substituted prolines / piperidines as orexin receptor antagonists NZ628491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596062P 2012-02-07 2012-02-07
PCT/US2013/024903 WO2013119639A1 (en) 2012-02-07 2013-02-06 Substituted prolines / piperidines as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
NZ628491A true NZ628491A (en) 2016-06-24

Family

ID=48947950

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628491A NZ628491A (en) 2012-02-07 2013-02-06 Substituted prolines / piperidines as orexin receptor antagonists

Country Status (18)

Country Link
US (2) US9499517B2 (enExample)
EP (1) EP2811997B1 (enExample)
JP (1) JP6346862B2 (enExample)
KR (1) KR20140124398A (enExample)
CN (1) CN104220065A (enExample)
AR (1) AR099466A1 (enExample)
AU (1) AU2013217323A1 (enExample)
BR (1) BR112014019426A8 (enExample)
CA (1) CA2863413A1 (enExample)
ES (1) ES2672732T3 (enExample)
HK (1) HK1204955A1 (enExample)
IL (1) IL234025A0 (enExample)
MX (1) MX2014009281A (enExample)
NZ (1) NZ628491A (enExample)
PH (1) PH12014501784A1 (enExample)
RU (1) RU2014136339A (enExample)
SG (1) SG11201404738QA (enExample)
WO (1) WO2013119639A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
ITMI20120322A1 (it) * 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
US9624197B2 (en) * 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
WO2015018027A1 (en) * 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Thiazole orexin receptor antagonists
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
TW201613891A (en) * 2014-02-12 2016-04-16 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
TW201613902A (en) 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
JP6715239B2 (ja) * 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用
JP2018016544A (ja) * 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ［２．２．２］オクタン誘導体
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
US10894789B2 (en) * 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна
CA3074059A1 (en) * 2017-09-01 2019-03-07 Chronos Therapeutics Limited Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
SG11202112828SA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
JPWO2022250108A1 (enExample) * 2021-05-26 2022-12-01

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049578A (en) * 1990-03-09 1991-09-17 E. R. Squibb & Sons, Inc. 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
CA2331735A1 (en) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
DE60013250T2 (de) 1999-02-12 2005-09-08 Smithkline Beecham P.L.C., Brentford Phenylharnstoff- und Phenylthioharnstoffderivate als Orexinrezeptorantagonisten
DE60015927T2 (de) 1999-02-12 2005-04-07 Smithkline Beecham P.L.C., Brentford Phenylharnstoff und phenylthioharnstoffderivate
WO2000071511A2 (en) * 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
WO2001085693A1 (en) 2000-05-11 2001-11-15 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
EP1289955B1 (en) * 2000-06-16 2005-04-13 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
US20040192673A1 (en) 2001-05-05 2004-09-30 Pascale Gaillard N-aroyl cyclic amine derivatives as orexin receptor antagonists
BR0209334A (pt) * 2001-05-05 2004-06-15 Smithkline Beecham Plc Aminas n-aroil cìclicas
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
JP4498922B2 (ja) 2002-07-09 2010-07-07 アクテリオン ファーマシューティカルズ リミテッド ７，８，９，１０−テトラヒドロ−６Ｈ−アゼピノ、６，７，８，９−テトラヒドロ−ピリドおよび２，３−ジヒドロ−２Ｈ−ピロロ［２，１−ｂ］−キナゾリノン誘導体
WO2004026866A1 (en) * 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
NZ538749A (en) 2002-10-11 2006-11-30 Actelion Pharmaceuticals Ltd Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
AU2003299648A1 (en) 2002-12-12 2004-06-30 Janssen Pharmaceutica, N.V. Substituted 4-phenyl-(1,3)-dioxanes
RU2345985C2 (ru) 2003-03-26 2009-02-10 Актелион Фармасьютиклз Лтд. Производные тетрагидроизохинолилацетамида в качестве антагонистов орексинового рецептора
ATE383345T1 (de) 2003-04-28 2008-01-15 Actelion Pharmaceuticals Ltd Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
HUP0304101A3 (en) 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
RU2378257C2 (ru) 2004-03-01 2010-01-10 Актелион Фармасьютиклз Лтд Замещенные производные 1,2,3,4-тетрагидроизохинолина
WO2006067224A2 (en) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
CA2603766A1 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Amidopropoxyphenyl orexin receptor antagonists
JP2008541698A (ja) 2005-05-03 2008-11-27 アンサンブル ディスカバリー コーポレイション 核酸検出のためのターンオーバープローブおよびその使用
US20090118200A1 (en) 2005-05-23 2009-05-07 Bergman Jeffrey M Proline bis-amide orexin receptor antagonists
CA2617324A1 (en) 2005-08-04 2007-02-15 Merck & Co., Inc. Aminoethane sulfonamide orexin receptor antagonists
JP2009506061A (ja) 2005-08-26 2009-02-12 メルク エンド カムパニー インコーポレーテッド ジアザスピロデカンオレキシン受容体拮抗薬
WO2007061763A2 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
CN101009515A (zh) 2006-01-24 2007-08-01 华为技术有限公司 通信终端设备管理方法及通信终端
TW200800020A (en) 2006-01-26 2008-01-01 Basf Ag Methods to use 3-pyridyl derivatives as pesticides
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
US20090105318A1 (en) 2006-03-29 2009-04-23 Coleman Paul J Amidoethylthioether Orexin Receptor Antagonists
JP2009533419A (ja) 2006-04-11 2009-09-17 アクテリオン ファーマシューティカルズ リミテッド 新規スルホンアミド化合物
DE602007012072D1 (de) 2006-04-26 2011-03-03 Actelion Pharmaceuticals Ltd Orantagonisten
WO2007143813A1 (en) 2006-06-16 2007-12-21 Husky Injection Molding Systems Ltd. Preventative maintenance update system
SI2049529T1 (sl) 2006-07-14 2010-11-30 Merck Sharp & Dohme Substituiran diazepan oreksin receptor antagonist
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
EP2049526A2 (en) 2006-07-14 2009-04-22 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
CA2659299A1 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds
ATE458740T1 (de) 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CN101568533A (zh) 2006-12-01 2009-10-28 埃科特莱茵药品有限公司 3-异芳基(氨基或酰胺基)-1-(联苯或苯基噻唑基)羰基哌啶衍生物食欲素受体抑制剂
AU2007337659A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
WO2008087611A2 (en) * 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
EP2131654A4 (en) 2007-03-02 2011-02-02 Merck Sharp & Dohme Bipyridine-carboxamide-orexin receptor Antagonist
EP2114867B1 (en) 2007-03-05 2012-12-12 F. Hoffmann-La Roche AG Aminoamides as orexin antagonists
AU2008225922B2 (en) 2007-03-15 2012-04-26 F. Hoffmann-La Roche Ag Malonamides as orexin antagonists
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CA2681163A1 (en) 2007-04-04 2008-10-16 F. Hoffmann-La Roche Ag Heterocycles as orexin antagonists
US20100222328A1 (en) 2007-05-14 2010-09-02 Hamed Aissaoui 2-cyclopropyl-thiazole derivatives
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
HRP20120240T1 (hr) * 2007-05-23 2012-04-30 Merck Sharp & Dohme Corp. Piridil piperidin antagonisti receptora za oreksin
US8106215B2 (en) * 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
KR20100046047A (ko) * 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
EP2185512B1 (en) 2007-07-27 2010-12-29 Actelion Pharmaceuticals Ltd. Trans-3-aza-bicyclo[3.1.0]hexane derivatives
BRPI0814767A2 (pt) 2007-08-02 2015-03-03 Hoffmann La Roche Derivados de monoamida como antagonistas do receptor de orexina
CA2695621A1 (en) 2007-08-09 2009-02-12 Merck Sharp & Dohme Corp. Pyridine carboxamide orexin receptor antagonists
ES2560095T3 (es) * 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
ES2400830T3 (es) 2007-08-15 2013-04-12 Actelion Pharmaceuticals Ltd. Derivados de 1,2-diamido-etileno como antagonistas de orexina
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
EP2214676B1 (en) 2007-10-29 2012-11-21 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
US8084464B2 (en) 2007-12-18 2011-12-27 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
KR101204213B1 (ko) 2007-12-21 2012-11-26 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 헤테로아릴 유도체
ATE511500T1 (de) 2008-01-21 2011-06-15 Hoffmann La Roche Sulfonamide als orexin-antagonisten
CN101918361B (zh) 2008-02-12 2014-05-28 弗·哈夫曼-拉罗切有限公司 哌啶磺酰胺衍生物
AU2009215243A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) * 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CA2726102A1 (en) 2008-06-11 2009-12-17 Actelion Pharmaceuticals Ltd Tetrazole compounds as orexin receptor antagonists
EP2297102A1 (en) 2008-06-16 2011-03-23 F. Hoffmann-La Roche AG Heteroaromatic monoamides as orexinin receptor antagonists
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물
WO2010004507A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
JP5301665B2 (ja) 2008-07-29 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー オレキシンアンタゴニストとしてのピロリジン−３−イルメチル−アミン
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
RU2011119217A (ru) 2008-10-14 2012-11-27 Актелион Фармасьютикалз Лтд Производные фенетиламида и их гетероциклические аналоги
JP2012506374A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
AU2009307921A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
AU2009307915A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
AU2009307920A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
AU2009307918A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
WO2010048013A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
EP2349262B1 (en) 2008-10-30 2014-06-25 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
EP2349267B1 (en) 2008-10-30 2014-06-25 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
EP2358712A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
CA2745433A1 (en) 2008-12-02 2010-06-10 Glaxo Group Ltd. N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
KR20110091581A (ko) 2008-12-02 2011-08-11 글락소 그룹 리미티드 Ｎ-｛［1ｒ,4ｓ,6ｒ-3-(2-피리디닐카르보닐)-3-아자비시클로［4.1.0］헵트-4-일］메틸｝-2-헤테로아릴아민 유도체 및 그의 용도
JP2010155827A (ja) 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
AR077525A1 (es) 2009-01-30 2011-09-07 Novartis Ag 4-aril-butan-1,3-diamidas y composiciones farmaceuticas
CN102459229A (zh) 2009-04-24 2012-05-16 葛兰素集团有限公司 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷
WO2011005636A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
EP2275421A1 (en) 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
WO2011016234A1 (en) * 2009-08-04 2011-02-10 Raqualia Pharma Inc. Picolinamide derivatives as ttx-s blockers
US20120149711A1 (en) * 2009-08-24 2012-06-14 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
EP2470523A1 (en) * 2009-08-24 2012-07-04 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
EP2493299A4 (en) 2009-10-29 2013-04-17 Merck Sharp & Dohme TERTIARY AMIDOREXIN RECEPTOR ANTAGONISTS
US20120258957A1 (en) 2009-11-23 2012-10-11 Matilda Jane Bingham Heterocyclic derivatives
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
US8530648B2 (en) 2009-12-21 2013-09-10 Novartis Ag Diaza-spiro[5.5]undecanes
ES2460915T3 (es) 2009-12-21 2014-05-16 Novartis Ag Piridinas fusionadas con heteroarilo disustituido
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2011138266A1 (en) 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
MX2013006715A (es) 2010-12-17 2013-08-26 Taisho Pharmaceutical Co Ltd Derivado de pirazol.
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
US20120165331A1 (en) 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
ES2541531T3 (es) 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US20140081025A1 (en) 2011-05-10 2014-03-20 Taisho Pharmaceutical Co., Ltd. Heteroaromatic ring derivative
EP2730573A4 (en) 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd METHYLPIPERIDINDERIVAT
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013059163A1 (en) 2011-10-21 2013-04-25 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
EP2771001A4 (en) 2011-10-25 2015-03-25 Merck Sharp & Dohme PIPERIDINYL-alkyne-orexin
US9242995B2 (en) 2011-10-25 2016-01-26 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
SI2776430T1 (sl) 2011-11-08 2016-06-30 Actelion Pharmaceuticals Ltd. 2-(1,2,3-triazol-2-il)benzamidni in 3-(1,2,3-triazol-2-il)pikolinamidni derivati kot antagonisti oreksinskega receptorja
ITMI20112329A1 (it) 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
US9416109B2 (en) 2012-02-17 2016-08-16 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
ITMI20120322A1 (it) 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
TW201613891A (en) 2014-02-12 2016-04-16 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists

Also Published As

Publication number Publication date
US20140364432A1 (en) 2014-12-11
WO2013119639A1 (en) 2013-08-15
KR20140124398A (ko) 2014-10-24
IL234025A0 (en) 2014-09-30
EP2811997B1 (en) 2018-04-11
JP2015506382A (ja) 2015-03-02
US9499517B2 (en) 2016-11-22
EP2811997A4 (en) 2015-07-22
AR099466A1 (es) 2016-07-27
EP2811997A1 (en) 2014-12-17
JP6346862B2 (ja) 2018-06-20
AU2013217323A1 (en) 2014-08-28
BR112014019426A8 (pt) 2017-07-11
CN104220065A (zh) 2014-12-17
RU2014136339A (ru) 2016-03-27
ES2672732T3 (es) 2018-06-15
SG11201404738QA (en) 2014-10-30
US20170101410A1 (en) 2017-04-13
BR112014019426A2 (enExample) 2017-06-20
PH12014501784A1 (en) 2014-11-10
MX2014009281A (es) 2015-01-12
US9896452B2 (en) 2018-02-20
CA2863413A1 (en) 2013-08-15
HK1204955A1 (zh) 2015-12-11

Similar Documents

Publication Publication Date Title
PH12014501784A1 (en) Substituted prolines / piperidines as orexin receptor antagonists
EA201390381A1 (ru) Триазиноксадиазолы
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
EA201401351A1 (ru) Производные бензимидазол-пролина
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
IN2014MN02598A (enExample)
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
PH12013500329A1 (en) New compounds
MX2015007936A (es) Inhibidores de autotaxina.
MX2014007897A (es) Nuevos derivados de azetidina, composiciones farmaceuticas y sus usos.
IN2015DN00185A (enExample)
UA107188C2 (uk) Карбоксамідні похідні хіназолінів або хінолінів та фармацевтична композиція на їх основі
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
IN2015DN03998A (enExample)
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
MX362879B (es) Usos novedosos.
IN2012DN01292A (enExample)
HK1204928A1 (en) Inhibitors of the notch signalling pathway and secretion for use in medicine
IN2014DN10449A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed